Invivyd (IVVD) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Entrada Therapeutics (TRDA) has outperformed Invivyd (IVVD) over the past year, losing 4.1% versus a loss of 55.3%. Entrada Therapeutics is the larger company by market cap ($218.4 million vs $214.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IVVD | TRDA |
|---|---|---|
| Share price | $0.7286 | $5.61 |
| Market cap | $214.76M | $218.43M |
| 1-day change | -9.65% | +3.51% |
| YTD return | -70.50% | -45.43% |
| 1-year return | -55.30% | -4.10% |
| 5-year return | -97.75% | — |
| EPS (TTM) | $-0.33 | $-3.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.07 | $16.45 |
| 52-week low | $0.528 | $5.15 |
| Distance from 52-week high | -76.27% | -65.90% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1272.50% | +238.68% |
| Average volume | 4.78M | 359.01K |
| Shares outstanding | 294.76M | 38.94M |
| Employees | 122 | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRDA has outperformed IVVD by 51.2 percentage points over the past year.
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
IVVD vs TRDA FAQ
Which is bigger, Invivyd or Entrada Therapeutics?
Entrada Therapeutics (TRDA) is larger, with a market capitalization of $218.43M compared with $214.76M for Invivyd (IVVD).
Which stock has performed better over the past year, IVVD or TRDA?
TRDA returned -4.10% over the past 12 months, compared with -55.30% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Invivyd and Entrada Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Invivyd and Biotechnology: Pharmaceutical Preparations for Entrada Therapeutics.